Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2019-03-20 Director's Dealing
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2019-03-20 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the securities to be registered, the plans involved, and signatures of company officers. This type of filing is related to share issuance and capital changes, specifically registering shares for employee compensation plans. It is not an annual report, earnings release, or any other financial report but a capital market filing related to share registration. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual registration statement, not just an announcement or a certification.
2019-03-14 English
FORM 3 -
Director's Dealing
2019-03-08 English
FORM 4 -
Director's Dealing
2019-03-07 English
10-K
Annual Report FY 2018
2019-03-01 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text includes an Item 1.01 describing entry into a material definitive agreement (a Co-Development and Commercialization Agreement) and Item 2.02 announcing financial results via a press release. The document explicitly states that the press release is furnished as an exhibit and is not filed as a formal earnings release. The document does not contain full financial statements or detailed financial analysis itself, but rather announces events and references other filings. Therefore, this is a regulatory announcement of material events and not a full financial report or earnings release. According to the classification rules, such filings are best categorized as Regulatory Filings (RNS).
2019-02-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.